Sanford J. Hillsberg Intends Not to Stand for Re-Election as Member of the Board of Directors of Iovance Biotherapeutics, Inc
March 15, 2018 at 02:06 am IST
Share
On March 9, 2018, Sanford J. Hillsberg, a member of the Board of Directors of Iovance Biotherapeutics, Inc. notified the Company that he will not be standing for re-election to the Board at the Company's annual meeting of stockholders currently anticipated to be held in June 2018. Mr. Hillsberg will serve out his current term. Mr. Hillsberg has advised the Company that his decision not to stand for re-election is because of personal and medical reasons, and not due to a disagreement with the company on any matter regarding its operations, policies or practices.
Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company develops and delivers tumor infiltrating lymphocyte (TIL), therapies for patients with solid tumor cancers. Its lead product candidate, Amtagvi (lifileucel), is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. The Company also marketing Proleukin (aldesleukin), aninterleukin-2, or IL-2, product used in the Amtagvi treatment regimen. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings for solid tumor cancers. Amtagvi and Proleukin are part of a treatment regimen that also includes lymphodepletion. The Company is also developing next generation therapies using TIL, such as genetically modified TIL cell therapy.
IOVANCE BIOTHERAPEUTICS, INC. 
